PROGNOSTIC SIGNIFICANCE OF GALECTIN-3 MEASUREMENT IN PATIENTS WITH METABOLIC SYNDROME AND NON-ALCOHOLIC FATTY LIVER DISEASE
Aim. To assess the levels of serum fibrosis marker (galectin-3) in patients with metabolic syndrome (MS) and non-alcoholic fatty liver disease (NAFLD)Material and methods. Totally 76 patients included, 43 with MS, of those 72,1% had the NAFLD diagnosed; 33 patients without MS and NAFLD (controls), m...
Saved in:
| Main Authors: | O. M. Drapkina, T. A. Deeva |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2015-10-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/164 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improvement of non-alcoholic fatty liver disease treatment
by: P. I. Seliverstov, et al.
Published: (2014-10-01) -
Sex-specific effect of dietary fatty acids on non-alcoholic fatty liver disease
by: Jianhua Chen, et al.
Published: (2025-07-01) -
Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia
by: Masahiro Kikuchi, et al.
Published: (2024-09-01) -
Hepatogenic weakness as a clinical marker of hyperammonemia and of the effectiveness of its correction in patients with pre-cirrhotic stages of non-alcoholic fatty liver disease
by: E. M. Petrova, et al.
Published: (2021-06-01) -
The effect of non-alcoholic fatty liver disease on the development of cardiovascular diseases
by: N. A. Starodubtseva, et al.
Published: (2025-03-01)